en
Scientific article
Open access
English

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

Published inDiabetes, Metabolic Syndrome and Obesity, vol. 13, p. 2359-2365
Publication date2020
Abstract

Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.

Keywords
  • Switzerland
  • Insulin glargine 300 U/mL
  • Real-world
  • Type 2 diabetes
Citation (ISO format)
THOMANN, Robert et al. Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland. In: Diabetes, Metabolic Syndrome and Obesity, 2020, vol. 13, p. 2359–2365. doi: 10.2147/DMSO.S252667
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1178-7007
239views
115downloads

Technical informations

Creation08/07/2020 8:24:00 AM
First validation08/07/2020 8:24:00 AM
Update time03/15/2023 10:46:53 PM
Status update03/15/2023 10:46:52 PM
Last indexation02/12/2024 1:19:20 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack